• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Canagliflozin Pharmacokinetics at Steady State in Patients on Maintenance Hemodialysis.

作者信息

Mavrakanas Thomas A, Marsot Amélie, Tsirella Efrosyne, Rios Norka, Gritsas Ari, Suri Rita S

机构信息

Division of Nephrology, Department of Medicine, McGill University Health Center, Montreal, Quebec, Canada.

Research Institute of the McGill University Health Center, Montreal, Quebec, Canada.

出版信息

Kidney Int Rep. 2024 Aug 8;9(10):3049-3052. doi: 10.1016/j.ekir.2024.07.038. eCollection 2024 Oct.

DOI:10.1016/j.ekir.2024.07.038
PMID:39430196
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11489451/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4af/11489451/7f1e4da271bf/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4af/11489451/7f1e4da271bf/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a4af/11489451/7f1e4da271bf/gr1.jpg

相似文献

1
Canagliflozin Pharmacokinetics at Steady State in Patients on Maintenance Hemodialysis.卡格列净在维持性血液透析患者体内的稳态药代动力学
Kidney Int Rep. 2024 Aug 8;9(10):3049-3052. doi: 10.1016/j.ekir.2024.07.038. eCollection 2024 Oct.
2
Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.氢氯噻嗪对钠-葡萄糖协同转运蛋白2抑制剂卡格列净在健康受试者中的药代动力学、药效学及耐受性的影响。
Clin Ther. 2014 May;36(5):698-710. doi: 10.1016/j.clinthera.2014.02.022. Epub 2014 Apr 13.
3
Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes.卡格列净在 2 型糖尿病儿科患者中的药代动力学和药效学。
Pediatr Diabetes. 2018 Jun;19(4):649-655. doi: 10.1111/pedi.12626. Epub 2017 Dec 22.
4
Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.卡格列净的药代动力学和药效学研究，一种钠-葡萄糖共转运蛋白 2 抑制剂，在 2 型糖尿病患者中的应用。
J Clin Pharmacol. 2013 Jun;53(6):601-10. doi: 10.1002/jcph.88. Epub 2013 May 14.
5
Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.钠-葡萄糖协同转运蛋白2选择性抑制剂卡格列净每日一次和每日两次多剂量给药在健康受试者中的药代动力学和药效学
Int J Clin Pharmacol Ther. 2015 Jun;53(6):438-46. doi: 10.5414/CP202324.
6
Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.肝肾功能损害对钠-葡萄糖协同转运蛋白2抑制剂卡格列净药代动力学的影响。
Clin Ther. 2015 Mar 1;37(3):610-628.e4. doi: 10.1016/j.clinthera.2014.12.013. Epub 2015 Feb 3.
7
Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men.接受维持性血液透析的终末期肾病男性和健康性腺功能减退男性使用透皮睾酮系统的药代动力学
J Clin Endocrinol Metab. 2001 Jun;86(6):2437-45. doi: 10.1210/jcem.86.6.7525.
8
Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.钠-葡萄糖协同转运蛋白2抑制剂卡格列净的临床药代动力学、药效学及药物相互作用特征
Clin Pharmacokinet. 2015 Oct;54(10):1027-41. doi: 10.1007/s40262-015-0285-z.
9
Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.钠葡萄糖协同转运蛋白2选择性抑制剂卡格列净在健康受试者中的单剂量和多剂量药代动力学及药效学研究
Int J Clin Pharmacol Ther. 2015 Feb;53(2):129-38. doi: 10.5414/CP202218.
10
Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects.单剂量卡格列净在健康中国受试者中的药代动力学、药效学及安全性
Clin Ther. 2015 Jul 1;37(7):1483-1492.e1. doi: 10.1016/j.clinthera.2015.04.015. Epub 2015 Jun 3.

引用本文的文献

1
Role of SGLT-2 Inhibitors in Ultrafiltration Failure in Peritoneal Dialysis: A Narrative Review.钠-葡萄糖协同转运蛋白2抑制剂在腹膜透析超滤失败中的作用：一项叙述性综述
Can J Kidney Health Dis. 2024 Nov 5;11:20543581241293500. doi: 10.1177/20543581241293500. eCollection 2024.

本文引用的文献

1
How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial.SGLT2 抑制剂如何保护肾脏？EMPA-REG OUTCOME 试验的中介分析。
Nephrol Dial Transplant. 2024 Aug 30;39(9):1504-1513. doi: 10.1093/ndt/gfae032.
2
SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis.SGLT-2 抑制剂可改善 CKD 患者的心血管和肾脏结局：系统评价和荟萃分析。
Sci Rep. 2023 Sep 23;13(1):15922. doi: 10.1038/s41598-023-42989-z.
3
Pharmacokinetic Properties of Dapagliflozin in Hemodialysis and Peritoneal Dialysis Patients.
达格列净在血液透析和腹膜透析患者中的药代动力学特征。
Clin J Am Soc Nephrol. 2023 Aug 1;18(8):1051-1058. doi: 10.2215/CJN.0000000000000196. Epub 2023 May 25.
4
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.糖尿病对钠-葡萄糖共转运蛋白 2 抑制剂肾脏结局影响的荟萃分析：大型安慰剂对照试验的协作荟萃分析。
Lancet. 2022 Nov 19;400(10365):1788-1801. doi: 10.1016/S0140-6736(22)02074-8. Epub 2022 Nov 6.
5
Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes.达格列净对 2 型糖尿病胰岛素治疗患者的血细胞比容、红细胞计数和网织红细胞的影响。
Sci Rep. 2020 Dec 28;10(1):22396. doi: 10.1038/s41598-020-78734-z.
6
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.卡格列净与 2 型糖尿病和肾病患者的肾脏结局。
N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.
7
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.卡格列净与 2 型糖尿病的心血管和肾脏事件。
N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.
8
Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.肝肾功能损害对钠-葡萄糖协同转运蛋白2抑制剂卡格列净药代动力学的影响。
Clin Ther. 2015 Mar 1;37(3):610-628.e4. doi: 10.1016/j.clinthera.2014.12.013. Epub 2015 Feb 3.
9
Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants.钠葡萄糖协同转运蛋白2选择性抑制剂卡格列净在健康受试者中的单剂量和多剂量药代动力学及药效学研究
Int J Clin Pharmacol Ther. 2015 Feb;53(2):129-38. doi: 10.5414/CP202218.